On the same day that health and wellness supplement provider Hims & Hers Health, Inc. announced it would begin selling a compounded semaglutide pill for weight loss at $49 for the first month, Novo Nordisk on Feb. 5 said it would take legal and regulatory action against the company for infringement of its intellectual property.
Novo Nordisk has manufactured its injectable drug Wegovy for weight loss since 2021 and announced on Jan. 5 that it would distribute the popular GLP-1 weight-loss drug as a daily oral pill.
Hims & Hers in a news release dated Feb. 5 stated that the telehealth provider will begin selling a new compounded semaglutide pill containing the same active ingredient as Wegovy.
The pill’s development was the result of significant investment in its pharmaceutical infrastructure in 2025 that included doubling the size of its operations in San Francisco to more than 1 million square feet and adding additional pharmacy, lab testing, and research and development space and capabilities, said the company.
“We have spent years building the infrastructure required to put the power of choice back into the hands of the individual, and we are committed to ensuring providers can always make the best clinical decision for their patients with an array of safe options to help find care that fits their lifestyle,” Andrew Dudum, co-founder and CEO of Hims & Hers, said.
Hims & Hers semaglutide pill has an introductory price point of $49 for the first month with a five-month subscription, and then jumps to $99 per month, though pricing can vary by plan, the company noted.
When Novo Nordisk introduced Wegovy in a daily oral pill, it came with an initial price of $149 monthly for a starter dose of 1.5 milligrams. The stronger 4 milligram dose was available for $149 through April, and then would jump to $199 per month. The highest doses, nine and 25 milligrams, cost $299 each month for a 30-day supply.
Hims & Hers said all active pharmaceutical ingredients for its compounded GLP-1 pill were sourced from Food and Drug Administration-registered facilities, but it also noted that compounded drugs were not FDA-approved for safety, effectiveness, or quality.
Compounded semaglutide that has not been approved by the FDA may contain impurities, unnecessary additives, and untested doses, Novo Nordisk said.
“The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety. Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the U.S. gold-standard drug approval framework,” it said.
“This is another example of Hims & Hers’ historic behavior of duping the American public with knock-off GLP-1 products, and the FDA has previously warned them about their deceptive advertising of GLP-1 knock-offs.”
A Hims & Hers spokesperson told The Epoch Times in a statement that the company’s track record speaks for itself.
“We’ve been able to help 2.5M customers access care personalized to their needs. We’re focused on bringing more access, more positive outcomes, and more choice to customers everywhere. That’s as true today as it was at our founding.
“This is not the first time—nor will it be the last time—a big pharma company has suggested taking an accessible, customer-first approach to healthcare is dangerous, illegal, or bad for the marketplace. This narrative is as predictable as it is outdated and false.”
Hims & Hers received a warning letter from the FDA in September 2025 for false and misleading claims about its compounded semaglutide products, specifically, injectable versions of Wegovy and Ozempic, which are prescribed for adult patients with Type-2 diabetes.
Hims & Hers said on its website that, “Weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy,” as well as the use of the language, “Clinically proven ingredients.”
“Compounded drug products are not FDA-approved,” the FDA’s Center for Drug Evaluation and Research wrote. “Your claims imply that your products are the same as an FDA-approved product when they are not.”
In addition to semaglutide products, Hims & Hers sells compounded drug products containing Sildenafil (generic Viagra) and Tadalafil (generic Cialis) in chew form, as well as Finasteride (Propecia, Proscar) and Minoxidil (Rogaine) for hair loss.
In November 2025, Hims & Hers reported updated fiscal revenue guidance for 2025 between $2.335 billion. The company had 2.47 million subscribers as of Sept. 30, 2025.
Friends Read Free
Copy
Facebook
Tweet
